| P2093 | author name string | Ke-Qin Hu | |
| | Jonathan Skupsky | |
| P2860 | cites work | Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels | Q80338898 |
| | Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers | Q80594566 |
| | Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation | Q81820230 |
| | Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers | Q82341792 |
| | Peginterferon plus adefovir versus either drug alone for hepatitis delta | Q83301804 |
| | Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B | Q84266979 |
| | An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients | Q84408961 |
| | Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients | Q84531673 |
| | A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B | Q84583821 |
| | Simultaneous quantitation of serum HBV DNA and HBeAg can distinguish between slow and fast viral responses to antiviral therapy in patients with chronic hepatitis B | Q84858365 |
| | Current trends in management of hepatitis B virus reactivation in the biologic therapy era | Q24634879 |
| | Telbivudine versus lamivudine in patients with chronic hepatitis B | Q28261708 |
| | EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 |
| | Chronic hepatitis B: update 2009 | Q29617409 |
| | Hepatitis B virus infection--natural history and clinical consequences | Q29617961 |
| | More than third of world's population has been infected with hepatitis B virus | Q33795374 |
| | Clinical relevance of hepatitis B viral mutations | Q33910174 |
| | A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection. | Q33959934 |
| | Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. | Q34007571 |
| | Management of hepatitis B: 2000--summary of a workshop | Q34263265 |
| | Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study | Q34317204 |
| | The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. | Q34318146 |
| | Epidemiology of hepatitis B infection in the Western Pacific and South East Asia | Q34441984 |
| | Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level | Q34481474 |
| | Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. | Q34500537 |
| | Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony | Q34502980 |
| | Lamivudine for patients with chronic hepatitis B and advanced liver disease | Q34551713 |
| | Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals | Q34674838 |
| | Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications | Q35597930 |
| | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update | Q35706189 |
| | Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel | Q36046987 |
| | Acute liver failure: Summary of a workshop | Q36054934 |
| | Redirecting T lymphocyte specificity by T cell receptor gene transfer--a new era for immunotherapy | Q36738848 |
| | Chronic hepatitis B: what should be the goal for new therapies? | Q36769986 |
| | Prophylaxis of hepatitis B infection in solid organ transplant recipients | Q36886518 |
| | GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees | Q36950984 |
| | Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment | Q37132382 |
| | A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update | Q37290723 |
| | National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. | Q37362846 |
| | Natural history of chronic hepatitis B virus infection and long-term outcome under treatment | Q37389943 |
| | Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia | Q37495081 |
| | Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus | Q45787408 |
| | Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: is the glass half full or half empty? | Q46156471 |
| | Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. | Q46217486 |
| | Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. | Q46907493 |
| | Predicting cirrhosis risk based on the level of circulating hepatitis B viral load | Q46985831 |
| | Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience | Q47212247 |
| | Chronic HBV infection outside treatment guidelines: is treatment needed? | Q47233507 |
| | Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. | Q51165652 |
| | Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. | Q51168753 |
| | Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. | Q52604921 |
| | Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. | Q53427565 |
| | Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results | Q57791894 |
| | Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy | Q58235736 |
| | Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B | Q61974430 |
| | Efficacy and limitations of a specific immunotherapy in chronic hepatitis B | Q62658364 |
| | Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing | Q72617595 |
| | Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B | Q73870637 |
| | Hepatitis B virus infection | Q73929492 |
| | Current management of hepatitis B virus infection before and after liver transplantation | Q37556630 |
| | The A, B, Cs of viral hepatitis in the biologic era. | Q37729774 |
| | Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action | Q37765836 |
| | A proposed, evidence-based approach to the treatment of chronic Hepatitis B. | Q37790595 |
| | Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options | Q37796726 |
| | Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges | Q37828959 |
| | Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review | Q37866717 |
| | The management of chronic hepatitis B in Asian Americans | Q37936321 |
| | Reactivation of hepatitis B virus in patients receiving chemotherapy | Q38062818 |
| | Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis. | Q38073460 |
| | Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs | Q38155954 |
| | Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation | Q39340555 |
| | Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia | Q39894574 |
| | Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference | Q39990948 |
| | Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. | Q40190157 |
| | The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection | Q41604051 |
| | Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. | Q42436412 |
| | Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States | Q42439943 |
| | Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update | Q42482272 |
| | Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers | Q42492983 |
| | Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. | Q42499453 |
| | Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection | Q42508945 |
| | Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline | Q42911213 |
| | Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. | Q42947269 |
| | Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses | Q42983894 |
| | Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir. | Q43136374 |
| | Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. | Q43223823 |
| | Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients | Q43288379 |
| | Hepatitis B virus genotypes in the United States: results of a nationwide study | Q43510252 |
| | European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. | Q43747979 |
| | Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. | Q44005581 |
| | Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir | Q44038236 |
| | Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy | Q44116666 |
| | Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection | Q44226733 |
| | Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels | Q44408807 |
| | Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients | Q44675031 |
| | Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients | Q44729139 |
| | Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels | Q44922285 |
| | Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. | Q45061899 |
| | Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. | Q45138388 |
| | Hepatitis B virus reactivation and alemtuzumab therapy | Q45252401 |
| | Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management | Q45268408 |
| | A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? | Q45367828 |
| | Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers | Q45375655 |
| | Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. | Q45378210 |
| | Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus | Q45384368 |
| | Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. | Q45385574 |
| | A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels | Q45392382 |
| | Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis | Q45784520 |
| P433 | issue | 2 | |
| P304 | page(s) | 145-157 | |
| P577 | publication date | 2014-05-29 | |
| P1433 | published in | Frontiers of medicine | Q26867043 |
| P1476 | title | Current hepatitis B treatment guidelines and future research directions | |
| P478 | volume | 8 | |